Quick Answer
ArriVent BioPharma, Inc. reported Research And Development Expense of $153.35 million for the year ending 2025.
- ArriVent BioPharma, Inc. showed an increase of +94.1% in Research And Development Expense from 2024 to 2025.
- This data is from ArriVent BioPharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $10.24 million | Q2 2023: $20.36 million | Q3 2023: $14.28 million | Q1 2024: $16.98 million | Q2 2024: $21.78 million | Q3 2024: $20.09 million | Q1 2025: $61.29 million | Q2 2025: $27.72 million | Q3 2025: $32.17 million.
- Over the full 3 years of available data (2023 to 2025), ArriVent BioPharma, Inc.'s Research And Development Expense has grown by 136.3%.
- Historical annual values: Fiscal year 2025: $153.35 million | Fiscal year 2024: $79.00 million | Fiscal year 2023: $64.88 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: